Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases.

Kwon MJ, Kang SY, Cho H, Lee JI, Kim ST, Suh YL.

Brain Pathol. 2019 Aug 21. doi: 10.1111/bpa.12782. [Epub ahead of print]

PMID:
31435963
2.

The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.

Lee Y, Koh J, Kim SI, Won JK, Park CK, Choi SH, Park SH.

Acta Neuropathol Commun. 2017 Aug 29;5(1):62. doi: 10.1186/s40478-017-0465-1.

3.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

4.

Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification.

Ochirjav E, Enkhbat B, Baldandorj T, Choe G.

J Pathol Transl Med. 2019 Sep;53(5):298-307. doi: 10.4132/jptm.2019.07.15. Epub 2019 Aug 2.

5.

Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.

Hinrichs BH, Newman S, Appin CL, Dunn W, Cooper L, Pauly R, Kowalski J, Rossi MR, Brat DJ.

Acta Neuropathol Commun. 2016 Jan 13;4:4. doi: 10.1186/s40478-015-0270-7.

6.

Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.

Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage CA, Eimer S, Polivka M, Vignaud JM, Laquerriere A, Sevestre H, Lechapt-Zalcman E, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel MC, Labrousse F, Chenard MP, Nguyen AT, Varlet P, Kemeny JL, Levillain PM, Cazals-Hatem D, Richard P, Delattre JY; POLA Network.

Brain Pathol. 2015 Jul;25(4):418-28. doi: 10.1111/bpa.12227. Epub 2014 Dec 31.

PMID:
25407774
7.

Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G.

Acta Neuropathol. 2016 Feb;131(2):309-319. doi: 10.1007/s00401-015-1495-z. Epub 2015 Oct 22. Erratum in: Acta Neuropathol. 2016 Feb;131(2):321-2.

8.

DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.

Paul Y, Mondal B, Patil V, Somasundaram K.

Clin Epigenetics. 2017 Apr 4;9:32. doi: 10.1186/s13148-017-0331-9. eCollection 2017.

9.

Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.

Akyerli CB, Yüksel Ş, Can Ö, Erson-Omay EZ, Oktay Y, Coşgun E, Ülgen E, Erdemgil Y, Sav A, von Deimling A, Günel M, Yakıcıer MC, Pamir MN, Özduman K.

J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16.

PMID:
28621624
10.

Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.

Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C, Hovestadt V, Bewerunge-Hudler M, Jones DT, Schittenhelm J, Mittelbronn M, Rushing E, Simon M, Westphal M, Unterberg A, Platten M, Paulus W, Reifenberger G, Tonn JC, Aldape K, Pfister SM, Korshunov A, Weller M, Herold-Mende C, Wick W, Brandner S, von Deimling A.

Acta Neuropathol. 2015 Sep;130(3):407-17. doi: 10.1007/s00401-015-1454-8. Epub 2015 Jun 19.

11.

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A.

Acta Neuropathol. 2015 Jan;129(1):133-46. doi: 10.1007/s00401-014-1370-3. Epub 2014 Nov 27.

12.

Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.

Malzkorn B, Reifenberger G.

Pathologe. 2019 Jun;40(Suppl 1):9-17. doi: 10.1007/s00292-019-0581-8. Review.

PMID:
31025086
13.

[Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].

Malzkorn B, Reifenberger G.

Pathologe. 2019 Mar;40(2):131-139. doi: 10.1007/s00292-019-0575-6. Review. German.

PMID:
30790013
14.

Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.

Suchorska B, Giese A, Biczok A, Unterrainer M, Weller M, Drexler M, Bartenstein P, Schüller U, Tonn JC, Albert NL.

Neuro Oncol. 2018 Jan 22;20(2):279-288. doi: 10.1093/neuonc/nox153.

15.

Anaplastic astrocytoma.

Grimm SA, Chamberlain MC.

CNS Oncol. 2016 Jul;5(3):145-57. doi: 10.2217/cns-2016-0002. Epub 2016 May 27. Review.

16.

Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.

Macaulay RJ.

Cancer Control. 2015 Apr;22(2):200-5. Review.

PMID:
26068765
17.

Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system.

Takei H, Shinoda J, Ikuta S, Maruyama T, Muragaki Y, Kawasaki T, Ikegame Y, Okada M, Ito T, Asano Y, Yokoyama K, Nakayama N, Yano H, Iwama T.

J Neurosurg. 2019 Aug 16:1-10. doi: 10.3171/2019.5.JNS19780. [Epub ahead of print]

PMID:
31419796
18.

Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.

Delfanti RL, Piccioni DE, Handwerker J, Bahrami N, Krishnan A, Karunamuni R, Hattangadi-Gluth JA, Seibert TM, Srikant A, Jones KA, Snyder VS, Dale AM, White NS, McDonald CR, Farid N.

J Neurooncol. 2017 Dec;135(3):601-609. doi: 10.1007/s11060-017-2613-7. Epub 2017 Sep 4. Erratum in: J Neurooncol. 2017 Sep 13;:.

19.

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.

Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D; For POLA Network.

Acta Neuropathol. 2016 Oct;132(4):625-34. doi: 10.1007/s00401-016-1611-8. Epub 2016 Aug 29.

PMID:
27573687
20.

A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up.

Rajeswarie RT, Rao S, Nandeesh BN, Yasha TC, Santosh V.

J Clin Pathol. 2018 Apr;71(4):323-329. doi: 10.1136/jclinpath-2017-204638. Epub 2017 Aug 11.

PMID:
28801347

Supplemental Content

Support Center